Stroke recurrence and cancer continue to pose significant challenges to global healthcare systems, contributing to high rates of morbidity, mortality, and financial burden. The emergence of COVID-19 has further complicated stroke prevention efforts, with studies highlighting an elevated risk of stroke following infection, attributed to increased inflammation and coagulation abnormalities. These insights reinforce the necessity for advanced, evidencebased strategies to enhance stroke prevention and management, ensuring better patient outcomes and healthcare resilience. Effective management of blood pressure and lipid levels, particularly the reduction of low-density lipoprotein cholesterol (LDL-C), is widely recognized as a cornerstone of stroke prevention. While lifestyle interventions, including dietary modifications and weight management, are frequently recommended to lower both blood pressure and LDL-C, these approaches require time and may present challenges, such as the rebound effect of LDL-C following statin discontinuation. A crucial question remains: at what LDL-C level can statin therapy be safely discontinued while maintaining a post-discontinuation LDL-C level of approximately 1.8 mmol/L (70 mg/dL)? Current guidelines suggest that targeting an LDL-C level of approximately 1.8 mmol/L is optimal for individuals with heart disease or those at high risk, as this threshold is associated with a lower likelihood of stroke recurrence. Identifying strategies to maintain this level post-statin therapy is essential for long-term cardiovascular and cerebrovascular health. While statins remain highly effective in managing LDL-C levels, prolonged use has raised concerns about potential associations with an increased risk of cancer. To address these challenges, this study introduces the Peter Chew LDL Rebound Formula, a novel, personalized approach to optimizing LDL-C regulation post-statin therapy. The formula integrates predictive modeling to tailor LDL-C management following statin discontinuation, coupled with lifestyle interventions such as dietary modifications and weight management. This combined strategy aims to minimize long-term statin dependency while sustaining optimal LDL-C levels. A unique case study, based on the author's personal experience, documents recovery from a mild stroke in July 2024. Within two months, LDL-C levels dropped from 3.1 mmol/L to 0.7 mmol/L, with predictive modeling estimating a post-statin discontinuation LDL-C level of 1.8 mmol/L. Subsequent blood tests conducted six months after statin cessation confirmed this prediction, reinforcing the real-world efficacy of the proposed formula. This research explores the broader implications of the Peter Chew LDL Rebound Formula in stroke recurrence prevention, cancer risk mitigation associated with extended statin use, and reducing global healthcare costs. By leveraging predictive analytics and lifestyle adjustments, this approach offers a data-driven, individualized strategy for long-term cardiovascular health.